Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
Company profile
Ticker
ALPMY, ALPMF
Exchange
Website
CEO
Kenji Yasukawa
Employees
Incorporated
Location
Fiscal year end
SEC CIK
ALPMY stock data
Latest filings (excl ownership)
F-6EF
Automatic registration for ADRs (foreign)
22 Nov 19
F-6EF
Automatic registration for ADRs (foreign)
21 Dec 17
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
29 Sep 17
F-6EF
Automatic registration for ADRs (foreign)
15 Oct 14
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
2 Apr 14
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
24 Mar 14
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
24 Mar 14
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
20 Mar 14
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
13 May 13
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
13 May 13
Latest ownership filings
No filings
Institutional ownership, Q2 2023
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 9 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 9.93 bn |
Total shares | 668.06 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Renaissance | 418.99 k | $6.23 bn |
Veredus Asset Management | 199.10 k | $2.96 bn |
Rhumbline Advisers | 34.74 k | $516.64 mm |
MAI Capital Management | 11.22 k | $166.83 mm |
Paradigm Asset Management | 2.50 k | $37.18 mm |
Cassady Schiller Wealth Management | 698.00 | $10.38 mm |
Russell Investments | 391.00 | $5.81 mm |
PNC PNC Financial Services | 172.00 | $2.56 mm |
First Horizon Advisors | 114.00 | $1.69 mm |
Motco | 91.00 | $1.35 mm |
Press releases
U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE
30 May 24
Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies
21 May 24
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
13 May 24
Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor
8 May 24
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
1 May 24